Kasabach-Merritt syndrome, first reported by Kasabach and Merritt in 1940, is a congenital disease characterized by large hemangiomas, thrombocytopenia, and purpura, mostly in infancy. This syndrome accounts for only 1% of the population with hemangiomas in infants and children, but the mortality rate is over 30%. Due to the large size of the hemangioma and the large amount of blood trapped in it, the child’s blood volume may be reduced, causing anemia, retention and consumption of large amounts of platelets, coagulation factors II, V, VIII and fibrinogen, resulting in abnormal coagulation mechanisms and a tendency to bleed. The treatment of Kasabach Merritt syndrome is mainly to eliminate the hemangioma and control the bleeding. The current treatment methods are: (1) glucocorticoid hormone therapy, if the conventional dose is ineffective, high-dose dexamethasone or methylprednisolone can be used; (2) radiotherapy: the dose is 100~150cGyö times, 4~10 times as a course of treatment. Because radiotherapy can cause a variety of sequelae, such as local growth disorders, bone destruction, induced malignant changes, so it should not be routinely applied; (3) embolization therapy, suitable for cases with clear vascular origin. (3) Embolization therapy is suitable for cases with clear vascular origin. Although this method can avoid the bleeding complications caused by surgery, if embolization is improper, the blood supply of important organs and tissues may be damaged, which may sometimes cause uncontrollable sepsis; (4) In different stages of D IC, anticoagulation and fibrinolytic inhibitors can be applied separately; in case of severe bleeding, platelets or fresh whole blood can be transfused. In addition, local compression and interferon can be applied.